Evidence map›Paper›PMID 38152333›Full record

ArticleOpen medicine (Warsaw, Poland)2023

FBLIM1 mRNA is a novel prognostic biomarker and is associated with immune infiltrates in glioma.

Yifan Deng, Kailiang Zeng, Diancheng Wu, Yunzhi Ling, Yu Tian, Yi Zheng, Shumin Fang, Xiaocong Jiang, Gang Zhu, Yanyang Tu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Cross-Species Upregulation ofCurrent issues in molecular biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yifan DengDepartment of Neurosurgery, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Kailiang ZengDepartment of Neurosurgery, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Diancheng WuDepartment of Neurosurgery, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Yunzhi LingResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Yu TianDepartment of Neurosurgery, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Yi ZhengResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Shumin FangResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Xiaocong JiangDepartment of Radiotherapy, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Gang ZhuDepartment of Neurosurgery, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Yanyang TuResearch Center, The Huizhou Central People's Hospital, Guangdong Medical University, Huizhou, Guangdong, China.
Huizhou Central People's Hospital · CNGuangdong Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioma is the most common primary brain tumor. Filamin-binding LIM protein 1 (FBLIM1) has been identified in multiple cancers and is suspected of playing a part in the development of tumors. However, the potential function of FBLIM1 mRNA in glioma has not been investigated. In this study, the clinical information and transcriptome data of glioma patients were, respectively, retrieved from the TCGA and CGGA databases. The expression level of FBLIM1 mRNA was shown to be aberrant in a wide variety of malignancies. Significantly, when glioma samples were compared to normal brain samples, FBLIM1 expression was shown to be significantly elevated in the former. A poor prognosis was related to high FBLIM1 expression, which was linked to more advanced clinical stages. Notably, multivariate analyses demonstrated that FBLIM1 expression was an independent predictor for the overall survival of glioma patients. Immune infiltration analysis disclosed that FBLIM1 expression had relevance with many immune cells. The results of RT-PCR suggested that FBLIM1 expression was markedly elevated in glioma specimens. Functional experiments unveiled that the knockdown of FBLIM1 mRNA suppressed glioma cell proliferation. In general, we initially discovered that FBLIM1 mRNA might be a possible prognostic marker in glioma.

Indexed as

bioinformatics analysisbiomarkerFBLIM1 mRNAgliomaimmune cell infiltrationprognosis

Identifiers

PMID38152333
PMCPMC10751895
OpenAlexW4389830335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.